The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells

Journal of Investigative Dermatology

Volumn 131, Issue 2, 2011, Pages 468-479

  Niessner, Heike ^a   Beck, Daniela ^a   Sinnberg, Tobias ^a   Lasithiotakis, Konstantinos ^a   MacZey, Evelyn ^a   Gogel, Jeannette ^a   Venturelli, Sascha ^b   Berger, Alexander ^b   Mauthe, Mario ^a   Toulany, Mahmoud ^a   Flaherty, Keith ^c   Schaller, Martin ^a   Schadendorf, Dirk ^d   Proikas Cezanne, Tassula ^a   Schittek, Birgit ^a   Garbe, Claus ^a   Kulms, Dagmar ^e   Meier, Friedegund ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e UNIVERSITY OF STUTTGART   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN HOMOLOGOUS PROTEIN; LONAFARNIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN FARNESYLTRANSFERASE; PROTEIN KINASE B; PROTEIN MCL 1; SORAFENIB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR P8; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER INVASION; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL MODIFICATION; DOWN REGULATION; DRUG POTENTIATION; FARNESYLATION; HUMAN; HUMAN TISSUE; MELANOMA CELL; PRIORITY JOURNAL; TUMOR GROWTH; UPREGULATION;

EID: 78651404680     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2010.297     Document Type: Article

References (38)

1. Bai X, Ma D, Liu A et al. (2007) Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science 318:977-80
2. Basso AD, Mirza A, Liu G et al. (2005) The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. J Biol Chem 280:31101-8
3. Chapman P, Puzanov I, Sosman J et al. (2009) Early efficacy signal demonstrated in advanced melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032. Euro J Cancer Suppl 7:5
4. Craig RW (2002) MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 16:444-54
5. Dai DL, Martinka M, Li G (2005) Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol 23:1473-82
6. Davies H, Bignell GR, Cox C et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-54
7. Eisen T, Ahmad T, Flaherty KT et al. (2006) Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 95:581-6
8. Flaherty KT (2006) Chemotherapy and targeted therapy combinations in advanced melanoma. Clin Cancer Res 12:2366s-70s
9. Hersey P (2006) Apoptosis and melanoma: how new insights are effecting the development of new therapies for melanoma. Curr Opin Oncol 18:189-96
10. Karasarides M, Chiloeches A, Hayward R et al. (2004) B-RAF is a therapeutic target in melanoma. Oncogene 23:6292-8
11. Karbowniczek M, Zitserman D, Khabibullin D et al. (2010) The evolutionarily conserved TSC/Rheb pathway activates Notch in tuberous sclerosis complex and Drosophila external sensory organ development. J Clin Invest 120:93-102
12. Lasithiotakis KG, Sinnberg TW, Schittek B et al. (2008) Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol 128:2013-23
13. Liu Z-J, Xiao M, Balint K et al. (2006) Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and upregulating N-cadherin expression. Cancer Res 66:4182-90
14. Mancianti ML, Herlyn M, Weil D et al. (1988) Growth and phenotypic characteristics of human nevus cells in culture. J Invest Dermatol 90:134-41
15. Margolin K, Longmate J, Baratta T et al. (2005) CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 104:1045-8
16. Mavrakis KJ, Zhu H, Silva RL et al. (2008) Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev 22:2178-88
17. Meier F, Busch S, Lasithiotakis KG et al. (2007) Combined targeting of MAPK and AKT signaling pathways is a promising strategy for melanoma treatment. Br J Dermatol 156:1204-13
18. Meier F, Nesbit M, Hsu MY et al. (2000) Human melanoma progression in skin reconstructs: biological significance of bFGF. Am J Pathol 56:193-200
19. Meier F, Schittek B, Busch S et al. (2005) The RAS/RAF/MEK/ERK and PI3K/ AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci 10:2986-3001
20. Mills JR, Hippo Y, Robert F et al. (2008) mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci USA 105: 10853-8
21. Molhoek KR, Brautigan DL, Slingluff CLJ (2005) Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J Transl Med 3:39
22. Rahmani M, Davis EM, Bauer C et al. (2005) Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem 280:35217-27
23. Rahmani M, Davis EM, Crabtree TR et al. (2007) The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol 15:5499-513
24. Rao RD, Allred JB, Windschitl HE et al. (2007) N0377: results of NCCTG phase II trial of the mTOR inhibitor RAD-001 in metastatic melanoma. J Clin Oncol 25:18s
25. Salazar M, Velasco G, Salanueva IJ et al. (2009) Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest 119:1359-72
26. Satyamoorthy K, Li G, Gerrero MR et al. (2003) Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 63:756-9
27. Sebti SM, Der CJ (2003) Opinion: searching for the elusive targets of farnesyltransferase inhibitors. Nat Rev Cancer 3:945-51
28. Sinnberg T, Lasithiotakis K, Niessner H et al. (2009) Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozo-lomide. J Invest Dermatol 129:1500-15
29. Smalley KS, Eisen TG (2003) Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. Int J Cancer 105:165-75
30. Smalley KS, Haass NK, Brafford PA et al. (2006) Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 5:1136-44
31. Song R, Feng Q, Li Y-P et al. (2009) Phosphatase of regenerating liver-3 localizes to cytomembrane and is required for B16F1 melanoma cell metastasis in vitro and in vivo. PLoS ONE 4:e4450
32. Sun SY, Liu X, Zou W et al (2007) The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells. J Biol Chem 282:18800-9
33. Tallarida RJ (2000) Response surface analysis of drug combinations. In: Drug Synergism and Dose-Effect Data Analysis (Tallarida RJ, ed). CRC Press: Boca Raton, FL, 157-71
34. Toulany M, Baumann M, Rodemann HP (2007) Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity. Mol Cancer Res 5:863-72
35. Verhaegen M, Bauer JA, Martin De la Vega C et al. (2006) A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res 66:11348-59
36. Xing JZ, Zhu L, Jackson JA et al. (2005) Dynamic monitoring of cytotoxicity on microelectronic sensors. Chem Res Toxicol 18:154-61
37. Yu C, Bruzek LM, Meng XW et al. (2005) The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 24:6861-9
38. Zouboulis CC, Garbe C, Krasagakis K et al. (1991) A fluorometric rapid microassay to identify anti-proliferative compounds for human melanoma cells in vitro. Melanoma Res 1:91-5